ILD management and role of pharmacists in clinic
“The quality of what Pharmacy Management is putting on is simply streets ahead of anything else I’m seeing at the moment. Keep up the good work!”
Noel Wicks, Managing Director, Right Medicine Pharmacy Ltd, Stirling
|Satellite||ILD management and role of pharmacists in clinic|
|Speakers||Ms Marium Naqvi, Specialist ILD Pharmacist, Guy's and St Thomas' NHS Trust|
Marium Naqvi is a specialist ILD pharmacist at GSTT and teaches pharmacy undergraduates at UCL and KCL. Marium has developed her role in ILD and is an integral part of the multidisciplinary team, responsible for medicines review and optimisation in addition to prescribing personalised medicine. Research interests include the psychological impact of disease, adherence to therapy and the management of comorbidities with IPF. She has started some work to encourage early identification and diagnosis of IPF and also to improve the way patients with IPF access care. Marium has undertaken a Masters in Pharmacy Practice to assess the management of respiratory conditions in acute medicine. Her findings suggest patients need to be educated on self-management as well as when and how to access primary, secondary and tertiary care. She is working across her local areas to improve education and access to care for patients with ILD.
This session will offer an insight into the management of patients with interstitial lung disease (ILD). It is often difficult to characterise patients with ILD, but once the diagnosis is confirmed, it is important that we understand the different care pathways and treatment considerations for appropriate management. We will explore the role of the pharmacist in supporting patients with ILD and their impact on patient care. This includes focusing on the initial consultation with counselling on medications, medications review, de-prescribing inappropriate therapies, optimisation of comorbidities and personalised prescribing. We will also discuss the ongoing role of the pharmacist in managing and minimising adverse effects, ensuring adherence to therapy, managing comorbidities and co-prescribed therapies to offer best practice care to these patients.